They’re go­ing for it: David Liu’s pre­clin­i­cal biotech shoots for a (maybe $200M) IPO

Can a pre­clin­i­cal biotech with grand am­bi­tions, a star sci­en­tif­ic founder and en­thu­si­as­tic back­ers with deep pock­ets fly a big IPO against the gale force head­winds we’ve seen this year?

In this econ­o­my?

The peo­ple at Prime Med­i­cine, which bills it­self as a CRISPR 3.0 play, aim to find out if they can buck the trend — which has re­lent­ed enough to al­low for one up­sized biotech IPO to get through — and pos­si­bly help pry open a win­dow that was slammed shut at the be­gin­ning of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER